Daonil 5 mg - 30 Tablet

Antidiabetic agent belongs to Sulfonylurea group used in the treatment of type 2 diabetes mellitus.

Administer with meals at the same time each day.

Epigastric fullness, heartburn, nausea, hypersensitivity reaction (including erythema, maculopapular rash, morbilliform rash, pruritus, urticaria), disulfiram-like reaction, hypoglycemia, hyponatremia, weight gain, diuresis, hemolytic anemia, cholestatic jaundice, hepatic failure, hepatitis, accommodation disturbance, angioedema, arthralgia, blurred vision, bullous rash, erythema multiforme, exfoliative dermatitis, increased serum transaminases, myalgia and vasculitis.

-Should not be given to patients suffering from hypersensitivity to glyburide. -Should not be given to patients suffering from type 1 diabetes mellitus or diabetic ketoacidosis. -All sulfonylurea drugs are capable of producing severe hypoglycemia. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when ethanol is ingested, or when more than one glucose-lowering drug is used. It is also more likely in elderly patients, malnourished or debilitated patients, and in patients with severe renal and hepatic impairment, adrenal and/or pituitary insufficiency. -Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency may be at an increased risk of sulfonylurea-induced hemolytic anemia. -Use of glyburide is generally not recommended in chronic kidney disease. -Glyburide is not a drug of choice for the elderly because of its association with severe hypoglycemia. -Intensive glucose control (HbA1c <6.5%) has been linked to increased cardiovascular mortality. -For the diabetic patients who has undergone bariatric surgery: Use IR formulations after surgery to minimize the potential effects of bypassing stomach and proximal small bowel with gastric bypass or more rapid gastric emptying and proximal small bowel transit with sleeve gastrectomy. -In case of over dose be ready to tell or show what was taken, how much and when it happened, and seek immediate medical attention. For additional information call us on 16676. Always tell your physician your detailed medical history.

Store at room temperature.

-Alcohol (Ethyl): Sulfonylureas may enhance the adverse/toxic effect of alcohol. -Alpha-Lipoic Acid: May enhance the hypoglycemic effect of antidiabetic agents. -Amiodarone: May enhance the hypoglycemic effect of Sulfonylureas. -Antidiabetic agents: May enhance the hypoglycemic effect of hypoglycemia-associated agents. -Beta-blockers: May enhance the hypoglycemic effect of Sulfonylureas. -Carbocisteine: Sulfonylureas may enhance the adverse/toxic effect of Carbocisteine. -Chloramphenicol: May increase the serum concentration of Sulfonylureas. -Clarithromycin: May enhance the hypoglycemic effect of Sulfonylureas. -Dipeptidyl Peptidase-IV Inhibitors: May enhance the hypoglycemic effect of Sulfonylureas. -Direct acting antiviral agents (HCV): May enhance the hypoglycemic effect of antidiabetic agents. -Miconazole (Oral): May enhance the hypoglycemic effect of Sulfonylureas. -Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of agents with blood glucose lowering effects. -Quinolones: May enhance the hypoglycemic effect of agents with blood glucose lowering effects. -Salicylates: May enhance the hypoglycemic effect of agents with blood glucose lowering effects. -Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of agents with blood Glucose lowering effects. -Tetracyclines: May enhance the hypoglycemic effect of Sulfonylureas. -Thiazide diuretics: May diminish the therapeutic effect of antidiabetic agents. -Vitamin K Antagonists (eg, warfarin): Sulfonylureas may enhance the anticoagulant effect of Vitamin K antagonists. -Voriconazole: May increase the serum concentration of Sulfonylureas.

-Glyburide crosses the placenta. Severe hypoglycemia lasting 4 to 10 days has been noted in infants born to mothers taking a sulfonylurea at the time of delivery, long-term safety data are not available, and adverse events have been observed, glyburide should not be recommended for pregnant women. Agents other than glyburide are currently recommended to treat diabetes mellitus in pregnancy. -Glyburide may be present in breast milk, the relative infant dose (RID) of glyburide was calculated to be 0.08%, breastfeeding is considered acceptable when the RID of a medication is <10%, due to the potential for hypoglycemia in the breastfeeding infant, a decision should be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother. -Ask your physician before taking any medication during pregnancy and lactation.

SANOFI